埃及患有良性和晚期恶性泌尿系统疾病患者的尿促性腺激素肽（UGP）
Urinary gonadotropin peptide (UGP) in Egyptian patients with benign and advanced malignant urological disease.
作者信息
el-Ahmady O, Halim A B, Mansour O, Salman T, el-Din A G, Walker R P
机构信息
Tumor Marker Oncology Research Center, Al-Azhar University, Cairo, Egypt.
出版信息
Br J Cancer. 1996 Jun;73(12):1486-90. doi: 10.1038/bjc.1996.281.
Urinary gonadotropin peptide (UGP) levels were determined in urine samples from 450 Egyptian subjects to determine its relative level of expression in benign and malignant urological disease, and normal individuals. The mean UGP level in patients with bladder cancer was 44-fold higher than in patients with benign disease, and 81-fold higher than in normal individuals. At specificities of 95% and 100%, overall sensitivities of 73% and 60%, respectively, were observed for the detection of malignant disease. Mean UGP levels in patients with bladder cancer were significantly correlated with the stage and grade of malignant disease but did not vary significantly when stratified according to histological type of disease, nodal involvement or bilharzial association. UGP could be a potentially useful marker for the differentiation of benign from malignant urological disease.
对450名埃及受试者的尿液样本进行尿促性腺激素肽（UGP）水平测定，以确定其在良性和恶性泌尿系统疾病以及正常个体中的相对表达水平。膀胱癌患者的平均UGP水平比良性疾病患者高44倍，比正常个体高81倍。在检测恶性疾病时，特异性分别为95%和100%时，总体敏感性分别为73%和60%。膀胱癌患者的平均UGP水平与恶性疾病的分期和分级显著相关，但根据疾病的组织学类型、淋巴结受累情况或血吸虫病关联分层时，差异不显著。UGP可能是区分良性和恶性泌尿系统疾病的潜在有用标志物。
Zotero 插件